{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-054465","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2025-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.725959+00:00","generated_at":"2026-05-19T06:42:04.933460+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Jasper Therapeutics: 92% complete response in 180mg cohort of briquilimab SPOTLIGHT study in CIndU","bullets":["11 of 12 participants (92%) achieved complete response; 12 of 12 (100%) achieved clinical response within 8-week analysis.","Tryptase levels below lower limit of quantification in 10 of 12 (83%); no SAEs or grade 3+ AEs reported.","Response rapid: 66% achieved CR/PR by week 2; 58% maintained clinical response through week 8.","No hair/skin color changes; mild transient neutrophil drops in 6 of 12 (50%), median resolution 16 days.","Conference call and webinar on June 16, 2025 at 8:00 AM EDT to present data."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-054465","json":"https://secwatch.observer/filing/0001213900-25-054465.json","markdown":"https://secwatch.observer/filing/0001213900-25-054465.md","text":"https://secwatch.observer/filing/0001213900-25-054465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025054465/0001213900-25-054465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390025054465/ea0245793-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T06:42:04.933460+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}